Kowa Announces the Efficacy and Safety of a Novel Rho Kinase Inhibitor (K-115) in the Treatment of Glaucoma in ARVO 2011
Kowa Company Ltd, (Headquarters: Nagoya, Japan, President & CEO: Yoshihiro Miwa, "Kowa") today announced the results of two clinical studies and a non-clinical study of a drug candidate for glaucoma and ocular hypertension (K-115). The results were presented as three posters at The Association for Research in Vision and Ophthalmology (ARVO) 2011 meeting in Fort Lauderdale, Florida, USA. The results of the two clinical studies can be read as an E-poster on the ARVO 2011 website during and after the conference.
K-115, a Rho kinase inhibitor, lowers intraocular pressure (IOP) by increasing conventional aqueous outflow. Consequently, additive effects are anticipated when K-115 is used in combination with other anti-glaucoma drugs. K-115 will also be developed as monotherapy for glaucoma.
Based on the results of these Phase 2 studies, Kowa will continue its clinical development program in Japan and will initiate Phase 3 studies with the aim of achieving marketing authorization as the world's first Rho kinase inhibitor for the treatment of glaucoma and ocular hypertension.
Presentations accepted by ARVO 2011 are as follows:
- Phase 2 clinical pharmacology study: Efficacy and Safety of the Rho Kinase Inhibitor, K-115, over 24 Hours in Patients with Primary Open-angle Glaucoma and Ocular Hypertension (E-Poster Presentation)*
- Phase 2 dose-response study: Ocular Hypotensive Dose-response Efficacy and Safety of the Rho Kinase Inhibitor, K-115, in Patients with Primary Open-angle Glaucoma and Ocular Hypertension (E-Poster Presentation)*
- Non-clinical study: Ocular Hypotensive Mechanism Of K-115, A Rho-kinase Inhibitor, And Rho-kinase Expression In The Eye
*E-Poster can be browsed for 24 hours via ARVO2011 Online E-Poster Viewer System from May 01 to June 30, 2011
URL: http://www.arvo.org/EWEB/startpage.aspx?site=am2011
Kowa has made intraocular and lifestyle disease R&D priorities, and is endeavoring to develop and explore innovative medicines. In addition, Kowa focuses on three major activities: drug discovery, innovative formulation discovery, and the development of neo generics, and actively engages in R&D activities to satisfy unmet medical needs.
Contact:
Kowa Company, Ltd.
Kazuhiro Kachi, +81-3-3279-7392 (Japanese
inquiries only)
Fax: +81-3-3279-7250
or
Kowa Research
Institute, Inc.
Gary Gordon, +1-919-433-1607 (English Only)
Senior
Vice president
Operations
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global styrker platformen i Filippinerne med Du-Baladad and Associates3.5.2025 00:55:00 CEST | Pressemeddelelse
Andersen Global forstærker sit engagement i Asien og Stillehavsområdet gennem en samarbejdsaftale med Du-Baladad and Associates, et skatte- og virksomhedsservicefirma med base i Filippinerne. Firmaet blev grundlagt i 2009 af administrerende partner Benedicta Du-Baladad og tilbyder en bred vifte af ydelser, herunder skatterådgivning og -planlægning, transfer pricing, international skat, skattetvister og -retssager, compliance og bistand i forbindelse med incitamenter. Du-Baladad and Associates anerkendes konsekvent som et førende skattefirma i Filippinerne af Chambers and Partners, International Tax Review, The Legal 500 og Asialaw og servicerer multinationale virksomheder og store indenlandske selskaber på tværs af brancher, herunder inden for finansielle tjenesteydelser, energi, olie og gas, produktion, fast ejendom og teknologi. "Vores firma bygger på en helhedsorienteret tilgang til kunderne, som prioriterer praktiske og skræddersyede strategier til at styre risici og understøtte vo
Spatial Releases 2025 1.0.1 with Enhancements for CAD Translation, Model Simplification, and Mesh Preparation for Manufacturing and Simulation2.5.2025 16:47:00 CEST | Press release
Spatial Corp., the leading software development toolkit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, announces the 2025 1.0.1 release and updates across several product lines, reaffirming its commitment to providing innovative solutions for its customers in domains ranging from CAD to simulation, manufacturing, and beyond. The 2025 1.0.1 release delivers expanded functionality designed to streamline manufacturing and simulation workflows. Key highlights include a new custom feature detection API in ACIS for more efficient model simplification, expanded CAD format support—including STEP AP242 PMI writing—and continued enhancements to hidden-body removal. With this release, Spatial reduces manual tasks, increases fidelity in geometry translation, and strengthens its toolset for automated design-to-manufacture and design-to-simulation pipelines. 3D ACIS ModelerCustom Feature Detection (Beta): Model simplification often requires manual
Decent Cybersecurity Joins the Council of Slovak Exporters to Strengthen European Cybersecurity Exports2.5.2025 15:51:00 CEST | Press release
Decent Cybersecurity, a leading European provider of post-quantum security solutions, announces its membership in the Council of Slovak Exporters (CSE), reinforcing its commitment to expanding advanced cybersecurity exports across global markets. This strategic partnership combines Decent Cybersecurity's expertise in critical infrastructure protection with CSE's established export promotion platform. As a company holding national, EU, and NATO "Secret" level security clearances, Decent Cybersecurity brings specialized knowledge in post-quantum security, blockchain technology, and space traffic management solutions to the Council's network. "Joining the Council of Slovak Exporters represents a significant opportunity to strengthen Slovakia's position in the global cybersecurity market," said Matej Michalko, Founder and CEO of Decent Cybersecurity and a long-term expert on post-quantum cryptography and blockchain. "As cyber threats continue to evolve, our advanced solutions are increasin
Saudi Arabia Hosts EDGEx 2025, Pushing the Boundaries of Education2.5.2025 15:29:00 CEST | Press release
Saudi Arabia has taken another step forward in its educational reform journey with the successful conclusion of the International Education Exhibition (EDGEx), held from April 13–16, 2025. Organized by the Ministry of Education, the event convened education leaders, technology developers, and policymakers from around the world under the theme “Beyond Readiness.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250502190798/en/ Saudi Arabia Hosts EDGEx 2025, Pushing the Boundaries of Education (Photo: AETOSWire) Over four days, EDGEx welcomed more than 20,000 local and international visitors, including government representatives, senior educators, academics, business leaders, and professionals in the field. The exhibition served as a platform for dialogue, knowledge exchange, and cross-sector collaboration—bringing together institutions, companies, and decision-makers to explore how education and training can evolve in a rapidl
IFF Announces Tender Offers for Certain Outstanding Series of Notes2.5.2025 15:10:00 CEST | Press release
IFF (NYSE: IFF) announced today the commencement of tender offers to purchase for cash certain of its outstanding series of notes listed in the tables below (collectively, the “Notes”) for an aggregate purchase price, excluding accrued and unpaid interest, of up to $1.8 billion. Pool 1 Tender Offers Pool 1 Maximum Amount: $1.0 billion(1(a)) Title of Security CUSIP/ISIN Principal Amount Outstanding(in millions) Acceptance Priority Level(2) Series Tender Cap(3) U.S. Treasury Reference Security Bloomberg Reference Page Fixed Spread(4) Early Tender Payment (4)(5) 1.230% Senior Notes due 2025 459506AN1 U45950AE9 $1,000 1 $500 million 5.000% UST due 9/30/25 FIT3 + 0 bps $30 1.832% Senior Notes due 2027 459506AP6 U45950AF6 $1,200 2 $300 million 3.750% UST due 4/30/27 FIT1 + 75 bps $30 2.300% Senior Notes due 2030 459506AQ4 U45950AG4 $1,500 3 N/A 3.875% UST due 4/30/30 FIT1 + 110 bps $30 4.450% Senior Notes due 2028 459506AK7 US459506AK78 $400 4 N/A 3.750% UST due 4/15/28 FIT1 + 95 bps $30 Poo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom